| GLP-1 Agonists or Analogs | DPP-4 Inhibitors | |||||
|---|---|---|---|---|---|---|
| Exenatide ER (Bydureon) | Exenatide (Byetta) | Liraglutide (Victoza) | Sitagliptin (Januvia) | Saxagliptin (Onglyza) | Linagliptin (Tradjenta) | |
| Route | SQ | SQ | SQ | Oral | Oral | Oral |
| Dosing frequency | Once a week | Twice a day | Daily | Daily | Daily | Daily |
| Change in A1c, % | −1.6 | −0.9 | −1.1 | −0.5 | −0.5 | −0.4 |
| Change in weight, kg | −2.0 | −2.5 | −1.9 | −1.5 | −1.1 | −1.0 |
| Hypoglycemia | ± | ± | ± | — | — | — |
| Adverse GI effects | + | + + | + + | — | — | — |
| Approximate monthly cost of therapy ($),12 | 370 | 360 | 520 | 260 | 260 | 280 |
ER, extended release; GLP, glucagon-like peptide; DPP, dipeptidyl peptidase; GI, gastrointestinal; SQ, subcutaneously.